Acumen Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$123.8 | -$114.0 | -$61.1 | -$45.2 | -$19.6 |
| Net income | -$121.3 | -$102.3 | -$52.4 | -$42.9 | -$100.6 |
| Balance Sheet | |||||
| Total debt | $31.2 | $29.4 | — | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$115.6 | -$86.2 | -$43.1 | -$35.3 | -$18.0 |
Shares outstanding 72.2M · Free float 54.5%
Annual filing data through FY ended December 31, 2025; float as of September 3, 2026.